07.19.21
DFE Pharma, a provider of pharmaceutical excipient solutions, has launched Pharmacel sMCC 90, a silicified microcrystalline cellulose (MCC). Pharmacel sMCC 90 has been developed as the synergistic solution for challenging oral solid dosage formulations.
Among several advancements in formulation science, co-processed excipients are gaining popularity as they offer effective means to rapidly develop products for early human trials, while minimizing the risk to product quality.
According to the company, co-processing silicon dioxide with microcrystalline cellulose increases its surface area, resulting in enhanced powder flow, superior tabletability, thus providing formulation robustness.
Bas van Driel, CEO of DFE Pharma, said, “Pharmacel sMCC 90 is an ideal excipient that improves tablet compression and aids higher production speed, thereby enabling rapid formulation development. We always put innovation at the heart of our business, thereby bringing excipients with multiple functionality benefits to our customers to meet their formulation needs.”
According to the company, co-processing silicon dioxide with microcrystalline cellulose increases its surface area, resulting in enhanced powder flow, superior tabletability, thus providing formulation robustness.
Bas van Driel, CEO of DFE Pharma, said, “Pharmacel sMCC 90 is an ideal excipient that improves tablet compression and aids higher production speed, thereby enabling rapid formulation development. We always put innovation at the heart of our business, thereby bringing excipients with multiple functionality benefits to our customers to meet their formulation needs.”
